Regeneron Pharmaceuticals Inc (REGN)
Total asset turnover
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 13,044,200 | 13,025,200 | 12,601,200 | 12,306,100 | 12,113,500 | 13,654,100 | 14,171,800 | 16,451,800 | 16,014,400 | 13,499,700 | 12,328,800 | 9,147,000 | 8,455,000 | 8,201,600 | 7,974,500 | 7,957,900 | 7,839,900 | 7,598,200 | 7,213,600 | 6,889,000 |
Total assets | US$ in thousands | 33,080,200 | 32,163,300 | 30,657,500 | 30,059,900 | 29,214,500 | 27,677,800 | 27,205,800 | 26,348,700 | 25,434,800 | 23,671,500 | 21,485,900 | 17,772,200 | 17,163,300 | 16,084,000 | 14,428,700 | 15,757,500 | 14,805,200 | 13,939,300 | 13,173,600 | 12,854,800 |
Total asset turnover | 0.39 | 0.40 | 0.41 | 0.41 | 0.41 | 0.49 | 0.52 | 0.62 | 0.63 | 0.57 | 0.57 | 0.51 | 0.49 | 0.51 | 0.55 | 0.51 | 0.53 | 0.55 | 0.55 | 0.54 |
December 31, 2023 calculation
Total asset turnover = Revenue (ttm) ÷ Total assets
= $13,044,200K ÷ $33,080,200K
= 0.39
Regeneron Pharmaceuticals, Inc.'s total asset turnover has been gradually declining over the past few quarters, indicating a decrease in the efficiency of the company's asset utilization. The total asset turnover ratio measures a company's ability to generate sales from its assets, with a higher ratio typically indicating better efficiency.
In Q4 2023, the total asset turnover ratio was 0.40, which means that for every dollar of assets the company had, it generated $0.40 in sales. This ratio remained relatively stable compared to the previous three quarters, which all stood at 0.41. However, there was a notable drop from the previous year, where the ratio was 0.42 in Q4 2022.
Looking back further to Q3 and Q2 of 2022, the total asset turnover was higher at 0.50 and 0.52, respectively, indicating that Regeneron Pharmaceuticals was more efficient in generating sales from its assets during that period. The highest total asset turnover was recorded in Q1 2022 at 0.63, suggesting the company's assets were highly utilized to generate sales at that time.
Overall, the declining trend in total asset turnover for Regeneron Pharmaceuticals, Inc. from 2022 to 2023 may raise concerns about the company's asset efficiency and its ability to generate sufficient sales from its asset base. It would be important for the company to analyze the underlying reasons for this decline and consider strategies to improve its asset utilization in order to enhance overall performance and profitability.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Total Asset Turnover (Quarterly Data)